LENZ has 36-month beta value of 0.46. Analysts have mixed views on the stock, with 1 analysts rating it as a “buy,” 4 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for LENZ is 22.05M, and currently, short sellers hold a 9.54% ratio of that float. The average trading volume of LENZ on September 12, 2024 was 168.86K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
LENZ) stock’s latest price update
The stock of LENZ Therapeutics Inc. (NASDAQ: LENZ) has decreased by -11.78 when compared to last closing price of 23.94.Despite this, the company has seen a loss of -14.56% in its stock price over the last five trading days. seekingalpha.com reported 2024-08-30 that Graphite Bio reverse merged with Lenz Therapeutics to focus on presbyopia, a $3bn+ market impacting 1.8 billion people globally. LNZ100, a 1.75% Aceclidine eye drop solution, conducted two positive phase 3 clinical trials for presbyopia, showing promising results. LENZ has a market cap of $617mn, cash balance of $226mn, submitted an NDA in August, and has $500mn peak sales estimate.
LENZ’s Market Performance
LENZ Therapeutics Inc. (LENZ) has experienced a -14.56% fall in stock performance for the past week, with a -8.89% drop in the past month, and a 11.33% rise in the past quarter. The volatility ratio for the week is 6.58%, and the volatility levels for the past 30 days are at 5.65% for LENZ. The simple moving average for the past 20 days is -8.02% for LENZ’s stock, with a 24.63% simple moving average for the past 200 days.
Analysts’ Opinion of LENZ
Many brokerage firms have already submitted their reports for LENZ stocks, with H.C. Wainwright repeating the rating for LENZ by listing it as a “Buy.” The predicted price for LENZ in the upcoming period, according to H.C. Wainwright is $38 based on the research report published on August 12, 2024 of the current year 2024.
Leerink Partners gave a rating of “Outperform” to LENZ, setting the target price at $32 in the report published on April 15th of the current year.
LENZ Trading at -5.22% from the 50-Day Moving Average
After a stumble in the market that brought LENZ to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -18.04% of loss for the given period.
Volatility was left at 5.65%, however, over the last 30 days, the volatility rate increased by 6.58%, as shares sank -8.85% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +19.39% upper at present.
During the last 5 trading sessions, LENZ fell by -14.56%, which changed the moving average for the period of 200-days by +30.05% in comparison to the 20-day moving average, which settled at $22.86. In addition, LENZ Therapeutics Inc. saw 70.33% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at LENZ starting from Chevallard Daniel R., who purchase 3,188 shares at the price of $15.68 back on May 14 ’24. After this action, Chevallard Daniel R. now owns 3,188 shares of LENZ Therapeutics Inc., valued at $49,988 using the latest closing price.
MCCOLLUM JAMES W, the Director of LENZ Therapeutics Inc., purchase 31,332 shares at $15.99 during a trade that took place back on May 13 ’24, which means that MCCOLLUM JAMES W is holding 525,565 shares at $501,093 based on the most recent closing price.
Stock Fundamentals for LENZ
The total capital return value is set at -0.3. Equity return is now at value -34.67, with -29.53 for asset returns.
Based on LENZ Therapeutics Inc. (LENZ), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -55.86.
Currently, EBITDA for the company is -70.7 million with net debt to EBITDA at 1.43. The liquidity ratio also appears to be rather interesting for investors as it stands at 23.23.
Conclusion
To put it simply, LENZ Therapeutics Inc. (LENZ) has had a mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
